Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Instagram Outage Disrupts Thousands of U.S. Users 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 08, 2017 -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 9:45am ET in New York.
AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's pipeline includes ophthalmology programs in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia caused by mutations in the CNGB3 and CNGA3 genes, wet age-related macular degeneration and an optogenetics program with Bionic Sight.
A live audio webcast of the presentation will be accessible by visiting ir.agtc.com/events.cfm. A replay will be available on the company’s website following the event.
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's product pipeline includes ophthalmology programs in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration, and an optogenetics program with Bionic Sight. AGTC's non-ophthalmology programs include its adrenoleukodystrophy program and its otology program, which is in pre-clinical development, and the company expects to advance several otology product candidates into clinical development in the next few years. Each of AGTC's XLRS, XLRP and adrenoleukodystrophy programs are part of its collaboration and license agreement with Biogen. AGTC employs a highly-targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need that it believes are clinically feasible and present commercial opportunities. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products.
IR/PR CONTACTS: David Carey (IR) Lazar Partners Ltd. T: (212) 867-1768 [email protected] Corporate Contacts: Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected]
